Drug Trial Radar · NCT07324616
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jan 26, 2026
Primary completion
Apr 7, 2026
Study completion Apr 7, 2026
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
Conditions
- Hepatic Impairment (HI)
Interventions
EDG-7500Drug
Single dose of EDG-7500
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration time-curve from time zero to the last measured concentration (AUC0-last)Time frame: Pre-dose to day 10
- Area under the plasma concentration time-curve from time zero extrapolated to infinity (AUC0-inf)Time frame: Pre-dose to day 10
- Maximum observed plasma concentration (Cmax)Time frame: Pre-dose to day 10
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The University of Miami Division of Clinical Pharmacology
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.